Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Austin, Texas 78744


The purpose of this study is to evaluate the safety profile, tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) following single and multiple oral doses of BMS-963272 in healthy subjects.

Study summary:

Study Classification: Safety, PK/PD


For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs and clinical laboratory determinations - Body Mass Index (BMI) of 27 to 40 kg/m2 inclusive. BMI = weight (kg)/ [height (m)]2 - Females (not of childbearing potential and males, ages 18 to 55 years, inclusive. Female subjects must have documented proof that they are not of childbearing potential - Azoospermic males and women who are not of child-bearing potential (i.e. are postmenopausal or surgically sterile; see section 3.3.3 for the definition of WOCBP) are exempt from contraceptive requirements. However, women must still undergo pregnancy testing as described in this section Exclusion Criteria: - Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations beyond what is consistent with the target population - Any of the following on 12-lead electrocardiogram (ECG) prior to study drug administration, confirmed by repeat. i)PR ≥ 210 msec ii)QRS ≥ 120 msec iii)QT ≥ 500 msec iv)QTcF ≥ 450 msec - Positive urine screen for drugs of abuse - Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, or HIV-1, -2 antibody - Moderate anemia (hemoglobin < 11 g/dL for men and < 10 g/dL for women) - aspartate aminotransferase (AST) > 1.3x ULN - alanine aminotransferase (ALT) > 1.3x ULN - Total bilirubin > 1.3x upper limit of normal (ULN) - estimated glomerular filtration rate (eGFR) < 90 ml/min/1.73 m2 (calculated using CKD-EPI formula) - HbA1c > 6.5% - Fasting total cholesterol > 300 mg/dl - Fasting triglycerides > 400 mg/dl - Systolic blood pressure > 160 mm Hg and/or diastolic blood pressure > 95 mm Hg, confirmed by repeat measurement - History of any significant drug allergy (such as anaphylaxis or hepatotoxicity). - History of lactose intolerance



Primary Contact:


Backup Contact:


Location Contact:

Austin, Texas 78744
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.